Latest Financials News

Virgin Money UK, trading as Clydesdale Bank, has applied to the High Court for approval to transfer its entire banking business to Nationwide Building Society, pending a February 2026 hearing.

Island Pharmaceuticals has secured FDA confirmation that its antiviral Galidesivir can proceed under the Animal Rule pathway for Marburg virus, qualifying for a lucrative Priority Review Voucher. This regulatory milestone accelerates the drug’s path to approval and potential government stockpile inclusion.

New Hope Corporation reported a 7.1% rise in quarterly saleable coal production and a 15.5% jump in underlying EBITDA, driven by operational improvements and easing logistics. The company declared a fully franked dividend and set a cautiously optimistic FY26 production target amid ongoing challenges.

Nexion Group has finalized the sale of its Nexion Networks and Blue Sky Telecom subsidiaries, pivoting its focus towards AI-driven business intelligence through Fuse Forward.

Cann Group Limited reminds eligible shareholders that its Share Purchase Plan (SPP) closes today, offering new shares at a discount plus free attaching options, pending shareholder approval.

Diablo Resources has appointed Matthew Blumberg as a Non-Executive Director and brought on Ellis Martin as its U.S. Media and Investor Communications Advisor, signaling a strategic push into North American markets.

Zuleika Gold has finalized a $48 million settlement with Catalyst Metals, resolving a protracted legal battle over the Plutonic Gold Mine and clearing the way for renewed focus on growth.

Algorae Pharmaceuticals has launched a Loyalty Options Offer, allowing eligible shareholders to purchase options at a nominal price, aiming to reward loyalty and support future growth funding.

HMC Capital has secured an increased and extended revolving debt facility, enhancing its underwriting capacity and supporting strategic growth initiatives, including its energy transition efforts.

IperionX rebuffs short seller claims by highlighting robust US government support and accelerating titanium production scale-up in Virginia. The company secures over $59 million in funding and advances critical minerals projects toward commercial readiness.

Algorae Pharmaceuticals has announced a non-renounceable Loyalty Options Offer to eligible shareholders, aiming to raise up to $337,678 before costs, with potential additional capital of $4.7 million if all options are exercised. The capital raise supports the company’s pharmaceutical and AI research and development ambitions.

Race Oncology has announced pivotal new clinical trials for its lead asset RC220, aiming to accelerate regulatory approval in Acute Myeloid Leukemia and tackle resistance in Non-Small Cell Lung Cancer.